What Causes Knee Pain in Females: A Hormone-Cycle Framework for 2026

Introduction: Why “Wider Hips” Isn’t the Whole Answer

The numbers are difficult to ignore. Women develop knee osteoarthritis (OA) at a rate of roughly 21.7%, compared with 11.9% of men. Female athletes tear the anterior cruciate ligament (ACL) at two to eight times the rate of men in the same sports, and some data put that figure as high as nine times.

Most women searching for an explanation have already heard the standard answer: wider hips and weaker ligaments. That answer is not wrong, but it is incomplete. It does not explain why knee symptoms can shift from week to week, or why new pain often appears during pregnancy or perimenopause.

This article offers a more complete explanation by presenting a hormone-cycle framework that traces how estrogen, progesterone, and relaxin reshape knee ligament and cartilage biology across three life stages:

• The menstrual cycle
• Pregnancy
• Perimenopause and menopause

Unlike typical listicles, this guide separates settled science from research that is still debated. It closes by explaining how an accurate, female-specific diagnosis connects to non-surgical regenerative treatment options.

Beyond Wider Hips: Why the Standard Explanation Falls Short

Anatomy is real and it matters. The Q-angle measures the angle between the quadriceps muscle and the patellar tendon. A typical Q-angle is about 12 degrees in men and 17 degrees in women. Clinicians generally consider a female Q-angle normal if it stays under 22 degrees with the knee extended, compared with under 18 degrees for men. Many women also have a mild degree of genu valgum (knock-knee alignment), with the thighbones angling inward from hip to knee. Both features add stress to the joint.

Anatomy alone, however, offers only a static picture of risk. A woman’s hip width does not change from week to week, yet knee laxity and injury risk appear to. Skeletal structure also cannot explain why knee problems often surge around pregnancy and menopause.

A better model treats biomechanics and hormones as factors that interact dynamically, not as fixed risks that act independently. The element most consumer articles skip is the cyclical, hormone-driven biology of the ACL and the connective tissue around it.

The Hormone-Cycle Framework: How a Woman’s Knee Changes Across the Month

The central idea of the framework is that the ACL and surrounding soft tissue are not biologically static. They respond to circulating estrogen, progesterone, and relaxin in real time.

The stakes are high because of the ACL’s role in the knee. It provides roughly 87% of the total restraining force against anterior tibial translation, which is the forward sliding of the shinbone. Any hormonal change to the ACL’s structure therefore has an outsized effect on knee stability.

Estrogen and the Collagen Connection

Estrogen acts directly on ligament tissue, not only on reproductive organs. Fibroblasts, the cells that build and maintain the ACL, carry estrogen receptors.

The proposed mechanism works through collagen cross-linking:

1. Elevated estrogen is linked to decreased activity of lysyl oxidase (LOX).
2. LOX is the enzyme that catalyzes cross-linking between collagen and elastin fibers.
3. Less cross-linking produces a less stiff, more pliable ligament.

This effect is measurable: elevated estrogen increases anterior knee laxity. According to the American Orthopaedic Society for Sports Medicine, peak estrogen during the late follicular and ovulatory phases correlates with higher ACL injury risk.

The pattern does not appear limited to the knee. Research on hormonal fluctuation and ankle instability found that during ovulation, when estrogen peaks, women showed impaired balance, higher postural sway, greater ankle laxity, and decreased muscle and ligament tone. This suggests a body-wide connective-tissue response rather than an isolated knee phenomenon.

Relaxin: The Female-Specific Hormone Most Articles Ignore

Relaxin receptors are present on female ACLs but not on male ACLs. This structural sex difference is rarely covered in consumer health content.

Relaxin appears to work in two ways:

• It increases matrix metalloprotease activity. These enzymes break down structural proteins.
• It decreases collagen expression. This reduces the ligament’s ability to rebuild.

Together, these effects may weaken the ligament’s structural integrity. Relaxin’s action also adds to estrogen’s collagen-loosening effect, which can create cumulative laxity during certain hormonal windows.

Progesterone’s Role and the Follicular/Ovulatory Risk Window

Progesterone appears to counterbalance estrogen’s effect on the ACL. Research published in Bone & Joint Open suggests ACL injury risk may be highest during the follicular and ovulatory phases, when progesterone levels are too low to offset estrogen’s loosening influence.

In plain terms, the proposed cycle-based timeline looks like this:

• Early follicular phase (menstruation): Estrogen and progesterone are both relatively low.
• Late follicular and ovulatory phase: Estrogen peaks while progesterone remains low. This is the proposed highest-risk window for ligament laxity.
• Luteal phase: Progesterone rises and may help stabilize the ligament’s response to estrogen.

This is a framework for understanding risk patterns. It does not predict outcomes for any individual woman, because hormone levels and responses vary widely from person to person.

Where the Science Is Settled Versus Still Debated

Many competing articles state hormonal causation as unquestioned fact. The evidence is more nuanced than that.

Well supported:

• Estrogen receptors are present on ACL fibroblasts.
• Relaxin receptors appear on female, not male, ACLs.
• Knee laxity changes measurably across the menstrual cycle.
• Women have dramatically higher ACL injury and knee OA rates overall.

Still contested:

• A controlled study found no significant difference in lower-extremity injury risk between estrogen-peak and progesterone-peak days of a normal menstrual cycle.
• Research titled “Knee ligament mechanical properties are not influenced by estrogen or its receptors” concluded that estrogen alone may not clearly alter ligament mechanics. The same authors noted there is still no conclusive explanation for why women tear their ACLs more often.

The research is mixed for several reasons:

• Tracking the menstrual cycle accurately in field studies is difficult.
• Hormone levels vary significantly from one woman to another.
• Injury is multifactorial. Hormones, biomechanics, and neuromuscular control all play a role.

The honest conclusion is that hormones are one significant contributing factor among several, not a sole proven cause.

Why Oral Contraceptives Appear Protective

Retrospective studies suggest that women taking oral contraceptives may have a reduced risk of ACL injury.

The proposed mechanism is that hormonal contraceptives flatten natural estrogen and progesterone fluctuations. Without cyclical peaks, collagen cross-linking and ligament laxity may stay more stable across the month.

This remains an active research area. Ongoing clinical trials, including registered studies examining hormonal contraceptives and ACL injury incidence across cycle phases, continue to investigate the link, and the finding is not a settled recommendation.

This information is educational context within the hormone framework, not a treatment suggestion. Contraceptive decisions involve many health factors and should be discussed with a physician.

Pregnancy: When Relaxin Floods the Body

Relaxin is best known for loosening the pelvis to prepare for childbirth, but its effects are not limited to the pelvis. It relaxes ligaments throughout the body, including the ACL, MCL, PCL, and LCL in the knee. High relaxin levels during pregnancy can increase joint laxity and discomfort.

The clinical impact can be significant. In one study of multiparous pregnant women (women who had given birth before), 29% showed signs and symptoms of knee joint dysfunction, and 21 of 65 subjects showed an altered Q-angle.

The biomechanical chain works like this:

1. Pregnancy increases the Q-angle, producing more valgus alignment.
2. A larger Q-angle increases the lateral (outward) force on the kneecap.
3. That force can contribute to patellar subluxation (partial dislocation) and anterior knee pain.

Many women expect ligaments to tighten gradually as hormone levels normalize after delivery, and for many that is true. Knee instability, buckling, or pain that persists after the postpartum period, however, deserves a professional evaluation and should not be dismissed as temporary.

Perimenopause and Menopause: The Musculoskeletal Syndrome of Menopause

Researchers now use the term “musculoskeletal syndrome of menopause” to describe the joint pain, stiffness, and tissue changes linked to the menopausal transition. Almost no consumer health site covers it, even though it may affect more women than any other knee-pain driver.

A review in Climacteric found that musculoskeletal pain affects approximately 71% of perimenopausal women, who are at higher risk than premenopausal women.

The Cartilage-Estrogen Pathway

Estrogen receptors exist in chondrocytes (cartilage cells), synovial cells (which line the joint), and subchondral bone (the bone beneath cartilage). Falling estrogen can therefore affect the joint itself, not just bone density.

During the menopausal transition, declining estrogen increases arthralgia (joint pain) and pain sensitivity. In men, by contrast, testosterone is associated with higher pain thresholds.

Estrogen is not the only hormone involved. One study found that postmenopausal women with knee OA and high follicle-stimulating hormone (FSH) levels had more severe cartilage damage than a low-FSH group. This suggests a broader hormonal axis is at work.

What Hormone Therapy Research Reveals

In the Women’s Health Initiative, estrogen therapy reduced total joint replacement by 50% in highly adherent users. That is notable evidence of a hormonal link to joint degeneration.

Other findings point the same way:

• Postmenopausal women show higher OA prevalence and severity than premenopausal women, which supports estrogen’s protective role in cartilage and subchondral bone remodeling.
• Knee OA prevalence in women is 1.2 to 2.8 times higher than in men, and menopause is a major point where that gap widens.
• Meniscal tears of the body are more common in women, and women require repeat meniscal repair surgery 2.2 times more frequently than men.

This research is promising, but much of it is correlational. It supports the hormone-cartilage link without making hormone therapy a blanket recommendation for knee health. Any decision about hormone therapy should be made with a physician.

Anatomy and Biomechanics: The Other Half of the Equation

Q-angle and valgus alignment add to hormonal factors rather than compete with them.

Women also tend to move differently during landing and cutting. Common patterns include:

• Less hip and knee flexion (a stiffer landing)
• More knee valgus (knees collapsing inward)
• A higher quadriceps-to-hamstring activation ratio

Each of these patterns is linked to higher ACL injury rates. Cadaveric and biomechanical studies also show that female knees have greater valgus laxity and poorer dynamic control during landing than male knees.

Together, these findings form an integrated model. Hormones change the ligament at the tissue level, while anatomy and movement patterns change the load placed on that tissue. Combined, they explain the sex disparity better than either factor alone.

Two Different Female Knee Problems: PFPS Versus Osteoarthritis

“Female knee pain” covers at least two very different conditions.

Patellofemoral pain syndrome (PFPS), often called runner’s knee, mainly affects young, active women. It typically occurs without major structural changes, such as an elevated Q-angle or significant cartilage damage. Anterior knee pain affects about 25% of athletes, and more than 70% of cases occur between ages 16 and 25.

Common PFPS contributors include:

• Weak hip abductors
• Abnormal rearfoot eversion (the heel rolling inward)
• Imbalance between the vastus medialis and vastus lateralis muscles
• Tight hamstrings or iliotibial (IT) band

Osteoarthritis, by contrast, is a degenerative condition concentrated in postmenopausal women, where estrogen decline affects cartilage and bone.

The distinction matters clinically. A 22-year-old runner with maltracking needs a very different plan than a 58-year-old woman with cartilage loss, yet most online content blends the two into one generic list.

Why Women Still Develop Knee OA at Nearly Double the Rate of Men

Taken together, the framework shows that a woman’s knee experiences layered stresses that male physiology does not:

• Decades of monthly hormonal fluctuation affecting ligament laxity
• Pregnancy-related surges in relaxin and changes in alignment
• A steep drop in estrogen at menopause that affects cartilage and bone

The 21.7% versus 11.9% OA disparity is best understood as the downstream result of this hormonal and biomechanical history, not a single-cause phenomenon.

Some studies dispute a direct mechanical link between estrogen and ligament strength. Even so, the combined evidence from ACL, cartilage, and meniscal research points to a real, multifactorial sex-based disparity.

What This Means for Patients: Applying the Framework

These takeaways are meant to raise awareness, not replace medical advice:

• Cycle-phase awareness can help. Some athletes and coaches pay closer attention to training load, landing mechanics, and warm-ups during the late follicular and ovulatory window.
• Hip and glute strength matters. Strong hip abductors and glutes help control knee valgus and Q-angle-related stress.
• Pregnancy and menopause are distinct risk windows. New or worsening knee symptoms during these stages deserve attention.
• Symptom tracking is valuable. Recording when pain or instability occurs in relation to cycle phase, pregnancy stage, or menopausal status can give a provider useful diagnostic clues.

Identifying the underlying cause, whether hormonal, structural, or both, is the necessary first step before choosing any treatment.

From Diagnosis to Treatment: Non-Surgical Regenerative Options

Once a female-specific cause is identified, the next step is to evaluate targeted, non-surgical treatment rather than defaulting to surgery. Possible causes include ligament laxity, cartilage degeneration, meniscal wear, or PFPS-related tracking problems.

Unicorn Bioscience uses ultrasound and X-ray guidance to pinpoint the exact structures involved and to deliver injections accurately. This precision matters because hormone-driven changes can be subtle and limited to specific tissues.

The broader context also supports exploring non-surgical options first. Studies suggest that up to 80% of patients told they need total knee replacement may not actually require surgery.

Matching Regenerative Therapies to Female-Specific Causes

Several regenerative options may fit different causes:

• PRP (platelet-rich plasma): Uses concentrated platelets from the patient’s own blood to support healing in ligaments or soft tissue affected by hormone-related laxity or microtrauma.
• Stem cell therapy: May help address cartilage degeneration associated with estrogen decline during perimenopause and menopause.
• Hyaluronic acid injections: Lubricate the joint (viscosupplementation), which is relevant to the OA-related knee pain common in postmenopausal women.

Unicorn Bioscience personalizes treatment plans based on inflammation levels, age, injury type, hormonal life stage, medications, and the patient’s goals. This approach reflects the hormone-cycle framework described above. As the clinic notes, the FDA has not approved stem cell, PRP, or exosome products specifically for orthopedic conditions as of 2026. Treatments are administered within FDA regulatory frameworks.

Qualified candidates may receive treatment on the same day as their consultation. Locations in Texas, Florida, and New York offer convenient access.

Conclusion

Knee pain in women cannot be reduced to “wider hips.” It results from a dynamic interaction between estrogen, progesterone, and relaxin on one side and anatomy and biomechanics on the other, and that interaction changes across a woman’s life.

Some of the science is settled, including receptor biology, measurable laxity changes, and the large disparities in OA and ACL injury. Other questions, such as whether hormones directly cause mechanical changes in ligaments, remain open.

The critical first step toward effective care is identifying which life stage and mechanism applies: cycle-related, pregnancy-related, or menopause-related. Once the cause is clear, a non-surgical regenerative evaluation is a logical, evidence-informed next step.

Take the Next Step: Schedule a Female-Specific Knee Evaluation

Women experiencing persistent or cycle-linked knee pain can schedule a virtual or in-person consultation with Unicorn Bioscience for an imaging-guided evaluation. Each consultation considers hormonal life stage, anatomy, and injury history to build a personalized, non-surgical treatment plan.

Unicorn Bioscience has eight locations in Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, Boca Raton, and Manhattan, and also offers virtual consultations. Patients can call (737) 347-0446 to book.

“It’s just hormones” is not a diagnosis. Every woman with knee pain deserves a specific answer and a plan built around it.